• Adds novel, proprietary technology platform to Telix's development pipeline
• Acquires pipeline of multiple preclinically characterized theranostic assets
• Expands R&D capabilities with research team and facility

Telix Pharmaceuticals has announced the acquisition of a novel biologics platform and assets from ImaginAb Inc. The transaction adds a proprietary technology platform to generate unique theranostic (therapeutic + diagnostic) engineered antibodies as radiopharmaceutical targeting agents, as well as a pipeline of multiple preclinically characterized theranostic assets derived from the platform. The acquisition also includes a research team and facility to expand the platform and pipeline while adding new technical competencies to Telix. The deal provides Telix with multiple IND-ready assets, which combine the advantages of both antibodies and small molecules to enable rapid tumor uptake, high tissue penetration, and faster clearance from blood circulation. The acquired assets include lead compounds targeting high-value targets such as DLL3 and integrin αvβ6, which are overexpressed in various cancers with high unmet need. The transaction also enhances Telix's R&D capabilities, with the addition of a research and development laboratory, bioreactor for engineered antibody production, and in-house preclinical imaging and therapy study capabilities. Overall, the acquisition reinforces Telix's leadership position in theranostics and provides multiple opportunities to leverage the novel theranostic mechanism of action against high-value targets.

The acquisition of the novel biologics platform and assets from ImaginAb Inc. is expected to complement Telix's existing pipeline and manufacturing capabilities, while also expanding its R&D infrastructure and technical competencies. This transaction positions Telix to accelerate the development of new theranostic assets targeting high-value indications with significant unmet clinical need.